HK1212389A1 - 碳酸酐酶 相關標記和其用途 - Google Patents
碳酸酐酶 相關標記和其用途Info
- Publication number
- HK1212389A1 HK1212389A1 HK15102061.3A HK15102061A HK1212389A1 HK 1212389 A1 HK1212389 A1 HK 1212389A1 HK 15102061 A HK15102061 A HK 15102061A HK 1212389 A1 HK1212389 A1 HK 1212389A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- carbonic anhydrase
- related markers
- markers
- anhydrase
- carbonic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161550807P | 2011-10-24 | 2011-10-24 | |
PCT/US2012/061711 WO2013063130A1 (en) | 2011-10-24 | 2012-10-24 | Carbonic anhydrase ix-related markers and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1212389A1 true HK1212389A1 (zh) | 2016-06-10 |
Family
ID=47356277
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15102061.3A HK1212389A1 (zh) | 2011-10-24 | 2015-03-02 | 碳酸酐酶 相關標記和其用途 |
Country Status (7)
Country | Link |
---|---|
US (1) | US10195174B2 (zh) |
EP (1) | EP2771488B1 (zh) |
JP (1) | JP6259764B2 (zh) |
CN (1) | CN104136629B (zh) |
CA (1) | CA2853283C (zh) |
HK (1) | HK1212389A1 (zh) |
WO (1) | WO2013063130A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6683986B2 (ja) * | 2013-07-10 | 2020-04-22 | 国立大学法人 東京大学 | がん幹細胞分子マーカー |
JP6277894B2 (ja) * | 2014-07-08 | 2018-02-14 | 株式会社島津製作所 | 上皮間葉転換の有無を判別する方法 |
CN104630380B (zh) * | 2015-03-06 | 2016-08-24 | 河北医科大学第四医院 | 碳酸酐酶iv在制备肺腺癌诊断制剂中的应用 |
CN107158388B (zh) * | 2017-07-11 | 2021-03-23 | 上海市第一人民医院 | MIIP pS303阻断剂在制备抗肿瘤药物中的应用 |
AU2020348365A1 (en) * | 2019-09-18 | 2022-04-07 | Biomarker Strategies, Llc. | Methods to improve patient response to immune checkpoint inhibitors and functional tests to predict response |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5474796A (en) * | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
US20050048566A1 (en) | 2001-08-27 | 2005-03-03 | Delisi Charles | Apparatus, composition and method for proteome profiling |
AU2002351208A1 (en) | 2001-12-03 | 2003-06-17 | Abgenix, Inc. | Antibodies against carbonic anhydrase IX (CA IX) tumor antigen |
HUE028349T2 (en) | 2002-11-26 | 2016-12-28 | Inst Virology | CAIX-specific inhibitors |
US20100143247A1 (en) | 2004-11-24 | 2010-06-10 | St. George's Enterprises Limited | Diagnosis of prostate cancer |
EP1907858A4 (en) * | 2005-06-13 | 2009-04-08 | Univ Michigan | COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER |
RU2473555C2 (ru) | 2006-12-19 | 2013-01-27 | ДжинГоу, Инк. | Новые способы функционального анализа большого количества экспериментальных данных и групп генов, идентифицированных из указанных данных |
US20080255243A1 (en) * | 2007-04-13 | 2008-10-16 | Petricoin Emanuel F | Stat3 as a theranostic indicator |
GB0718167D0 (en) * | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
US20090123439A1 (en) * | 2007-11-09 | 2009-05-14 | The Jackson Laboratory | Diagnostic and prognosis methods for cancer stem cells |
US20100311084A1 (en) * | 2008-05-14 | 2010-12-09 | Precision Therapeutics, Inc. | Methods for predicting a patient's response to egfr inhibitors |
JP2010178650A (ja) | 2009-02-04 | 2010-08-19 | Univ Of Tokyo | 固形癌の再発予測のための試験方法および再発予防剤 |
US20100317533A1 (en) * | 2009-06-05 | 2010-12-16 | British Columbia Cancer Agency Branch | Biomarkers of cancer metastasis |
WO2011085263A2 (en) * | 2010-01-11 | 2011-07-14 | Genomic Health, Inc. | Method to use gene expression to determine likelihood of clinical outcome of renal cancer |
EP2590938B1 (en) | 2010-07-09 | 2017-06-07 | Welichem Biotech Inc. | Novel sulfonamide compounds for inhibition of metastatic tumor growth |
-
2012
- 2012-10-24 US US14/353,665 patent/US10195174B2/en active Active
- 2012-10-24 EP EP12799669.2A patent/EP2771488B1/en active Active
- 2012-10-24 CN CN201280064274.6A patent/CN104136629B/zh active Active
- 2012-10-24 WO PCT/US2012/061711 patent/WO2013063130A1/en active Application Filing
- 2012-10-24 CA CA2853283A patent/CA2853283C/en active Active
- 2012-10-24 JP JP2014538935A patent/JP6259764B2/ja active Active
-
2015
- 2015-03-02 HK HK15102061.3A patent/HK1212389A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CA2853283A1 (en) | 2013-05-02 |
JP6259764B2 (ja) | 2018-01-10 |
CA2853283C (en) | 2022-04-26 |
EP2771488A1 (en) | 2014-09-03 |
US20140303103A1 (en) | 2014-10-09 |
US10195174B2 (en) | 2019-02-05 |
CN104136629A (zh) | 2014-11-05 |
WO2013063130A1 (en) | 2013-05-02 |
EP2771488B1 (en) | 2018-03-28 |
JP2014532864A (ja) | 2014-12-08 |
CN104136629B (zh) | 2021-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1187049A1 (zh) | 雙芳基連接的芳基三唑酮及其用途 | |
ZA201308930B (en) | Nitrogen containing compounds and their use | |
HK1187337A1 (zh) | 喹唑啉二酮及其應用 | |
HK1182112A1 (zh) | 取代的 -氟- -吡唑並吡啶類化合物及其用途 | |
RS57375B1 (sr) | Heterociklični amini i njihove upotrebe | |
EP2707102A4 (en) | CARBOHYDRASE TARGETED ACTIVE SUBSTANCES AND METHOD FOR THEIR USE | |
IL225713A0 (en) | Cytopheric cartridge and its use | |
HK1198827A1 (zh) | 抑制劑及其用途 | |
IL229844B (en) | Anti-psgl-1 antibodies and their use | |
HK1191034A1 (zh) | -羧烷基耳他汀類及其應用 | |
GB201111705D0 (en) | Compounds and their use | |
GB201110783D0 (en) | Methods and uses | |
EP2738255A4 (en) | PEPTIDE FROM ERAP1 AND ITS USE | |
EP2749633A4 (en) | COMPOSITION WITH IMPROVED HEAD STABILITY AND USE THEREOF | |
IL232362A0 (en) | The chemical composition containing fluorine and its use | |
IL231082A0 (en) | Pyrimido-pyridazinone compounds and their use | |
ZA201400223B (en) | Improved spreader and use thereof | |
EP2841571A4 (en) | HUMAN CARBONIC II ANHYDRASE HAVING INCREASED PHYSICAL STABILITY | |
GB201116774D0 (en) | Uses and methods | |
HK1212389A1 (zh) | 碳酸酐酶 相關標記和其用途 | |
EP2697386A4 (en) | DESIGN AND USE OF PEPDUCINE | |
GB201114448D0 (en) | Compounds and their use | |
EP2693879A4 (en) | MIGRASTATINES AND THEIR USES | |
HK1198587A1 (zh) | 異噻唑並吡啶- -甲酰胺和它們作為藥物的用途 | |
GB201108490D0 (en) | Methods and uses |